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Abstract
Background: The neuropeptide, calcitonin gene-related peptide (CGRP) has been proposed to be a regulator of
the development of morphine analgesic tolerance and thereby could be a target to reduce the induction of this
phenomenon under clinical conditions. However, the mechanisms of CGRP regulation are unclear. We investigated
here the possible role of the extracellular signal-regulated protein kinase (ERK), p38 and calcium/calmodulin-
dependent protein kinase II (CaMKII) in CGRP regulation following chronic morphine treatment.
Results: A 7-day treatment with morphine (15 μg/day) led to an increase in CGRP contents in the spinal cord
dorsal horn (SCDH) and dorsal root ganglion (DRG) and this effect was prevented by the inhibition of the ERK, p38
or CaMKII pathway. The phosphorylation/activation of ERK, p38 and CaMKII was enhanced in the SCDH following
chronic morphine while in DRG only the phosphorylation of CaMKII was increased. Moreover, our chronic
morphine treatment up-regulated neuronal nitric oxide synthase (nNOS) levels in the SCDH, an effect blocked by
the inhibition of the ERK, p38 or CaMKII pathway. The blockade of nNOS activity also suppressed chronic
morphine-induced CGRP increases in the DRG and SCDH. Double immunofluorescence studies revealed that nNOS
and CaMKII are co-localized in the SCDH and that CaMKII is activated in CGRP-expressing DRG neurons.
Conclusions: The activation of spinal ERK, p38 and CaMKII, alongside nNOS, is involved in chronic morphine-
induced CGRP up-regulation in both the DRG and SCDH. Moreover, the stimulation of CaMKII in the DRG likely
directly regulates the expression of CGRP associated with morphine analgesic tolerance.
Keywords: CGRP, ERK, p38, CaMKII, morphine
Background
Opiates such as morphine are the most commonly used
drugs in the clinical management of moderate to severe
pain, including cancer pain. However, their clinical use-
fulness is largely hindered by the development of analge-
sic tolerance, which often requires escalating doses to
achieve equivalent pain relief [1]. The mechanisms
underlying this phenomenon have been extensively
investigated and several hypotheses have been proposed,
including the altered activity of excitatory substances
and their intracellular signaling pathways, the desensiti-
zation of mu-opioid receptor and its possible linkage
with arrestin as well as interaction between mu- and
delta-opioid receptors [2]. In accordance with these
data, a neuropeptide, calcitonin gene-related peptide
(CGRP), has been suggested to play a major role in the
development of tolerance to morphine-induced analgesia
[3-7] and thus could be a promising target to reduce the
occurrence of tolerance. Indeed, chronic morphine treat-
m e n tr e s u l t si na ni n c r e a s ei nC G R Pe x p r e s s i o na n d / o r
release in the spinal cord [3,5,6,8,9]. Moreover, treat-
ment with a CGRP receptor antagonist was shown to
prevent the development of tolerance to morphine-
induced analgesia [3,4]. Furthermore, the role of CGRP
in morphine tolerance may be attributable to its differ-
ential regulation of cell-type specific kinase-transcription
factor cascades [5,6]. Accordingly, it is of interest to
investigate how the expression of CGRP is regulated fol-
lowing chronic morphine treatment.
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tributed in the peripheral and central nervous systems,
including the dorsal root ganglion (DRG) and its nerve
terminals, which are the predominant source of CGRP
in the spinal cord dorsal horn (SCDH) [10]. Mounting
evidence has suggested that various factors influence
CGRP expression under certain conditions. For example,
CGRP levels can be increased in vivo or in vitro by
growth factors such as nerve growth factor (NGF) or
the cytokine activin A in sensory neurons [11-16]. In
particular, peripheral stimulation such as inflammation
can induce an increase in CGRP mRNA levels in the
DRG, possibly through the synergistic effect of NGF and
activin A [17]. Our previous results have also shown
that chronic morphine-induced increases in CGRP levels
may result from the activation of ERK and the down-
stream cAMP response element-binding protein (CREB)
in cultured DRG sensory neurons [18]. In the present
study, we investigated factors involved in the regulation
of the expression of CGRP and associated with the
development of tolerance to morphine-induced analgesia
both at the level of the DRG and SCDH.
Results
Possible role of ERK, p38 and CaMKII in the development
of morphine antinociceptive tolerance
We have previously shown that the development of
CGRP-associated tolerance to morphine-induced analge-
sia involves the activation of ERK, p38 and CaMKII
[5,6]. As shown in Figure 1, an acute morphine treat-
ment (15 μg) produced analgesia on day 1 as revealed
by an increase in paw-withdrawal response. In contrast,
a 7-day daily intrathecal delivery of morphine (15 μg/
day) led to decreased paw-withdrawal responses. This
effect was attenuated by a co-treatment with PD98059
(10 μg ) ,aM E K( E R Ku p s t r e a mk i n a s e )i n h i b i t o r ,
SB203580 (10 μg), a p38 inhibitor as well as KN93 (15
nmol), a CaMKII inhibitor (two way repeated ANOVA,
F(4,71) = 68.877, p < 0.001). Furthermore, the 7-day
treatment with morphine produced a shift in the dose-
response curve, which was attenuated by the co-admin-
istration of PD98059 (10 μg), SB203580 (10 μg) or
KN93 (15 nmol) (Figure 2) (one way ANOVA, F(7,47) =
253.198, p < 0.001). These inhibitors by themselves did
not influence the shift in the dose-response curve when
compared with the saline group (Figure 2).
Involvement of ERK, p38 and CaMKII in CGRP regulation
related to morphine antinociceptive tolerance
Chronic morphine treatments have been shown to
increase CGRP levels in primary afferent terminals of
the spinal dorsal horn [3,5,6,8]. Accordingly, we investi-
gated next if ERK, p38 and CaMKII are implicated in
the regulation of CGRP expression following repeated
treatments with morphine. As shown in Figure 3, a 7-
day intrathecal delivery of morphine (15 μg/day)
increased CGRP levels in the spinal cord dorsal horn, as
revealed by western blot (Figure 3A; two way ANOVA,
F(4,19) = 13.400, p < 0.001) and immunohistochemical
(Figure 3B and 3C) analyses. This effect was inhibited
by the co-administration of PD98059 (10 μg), SB203580
(10 μg) or KN93 (15 nmol). A 7-day daily injection of
these inhibitors by themselves failed to alter CGRP
levels (additional file 1, figure 1; one way ANOVA, F
(3,15) = 0.916, p = 0.462). In addition, the levels of phos-
phorylated ERK (two way ANOVA, for p-ERK1 F(3,15) =
22.248, p < 0.001; for p-ERK2, F(3,15) = 34.437, p <
0.001), p38 (two way ANOVA, F(3,15) = 25.351, p <
0.001) and CaMKII (two way ANOVA, F(3,15) = 58.368,
p < 0.001), indicative of their activation, were increased
in the spinal dorsal horn following repeated morphine
treatment (Figure 4).
Since DRG neurons are the predominant source of
CGRP in the spinal cord dorsal horn [10], we examined
next the changes in CGRP expression at the DRG level.
CGRP levels were up-regulated following a 7-day
intrathecal injection of morphine (15 μg/day) (Figure 5,
two way ANOVA, F(4,19) = 12.036, p < 0.001). This up-
regulation was prevented by the inhibition of ERK
(PD98059, 10 μg), p38 (SB203580, 10 μg) and CaMKII
(15 nmol) pathways (Figure 5). Interestingly, the 7-day
treatment with morphine did not increase the levels of
phosphorylated ERK and p38, but indeed increased p-
CaMKII level (Figure 6). The confocal study showed
that CGRP is also present in p-CaMKII-expressing cells,
suggesting their co-localization(Figure 7).
Possible role of nNOS in the regulation of CGRP by ERK,
p38 and CaMKII during the development of morphine
tolerance
It has been proposed that spinal nitric oxide (NO) can
act as a retrograde signaling molecule to influence
CGRP release from presynaptic primary afferent term-
inals in the spinal dorsal horn [19]. To investigate the
possible role of NO in the regulation of CGRP expres-
sion in this region, we used (4S)-N-(4-Amino-5[ami-
noethyl]aminopentyl)-N’-nitroguanidine, TFA (NG) and
7-Nitroindazole (7-NI) to specifically inhibit neuronal
NO synthase (nNOS). We first determined the nNOS
levels following a chronic morphine treatment. A
repeated treatment with morphine (15 μg/day) for 7
days markedly increased nNOS expression (Figure 8,
two way ANOVA, F(4, 19) = 17.471, p < 0.001) while
inducible NOS (iNOS) and endothelial NOS (eNOS)
levels were not changed (data not shown). This increase
was inhibited by a co-treatment with PD9059 (10 μg),
SB203580 (10 μg) or KN93 (15 nmol), suggesting a role
for these kinases in our model (Figure 8). In contrast, a
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Page 2 of 12Figure 1 Inhibition of the development of tolerance to morphine-induced analgesia by the co-administration of various inhibitors.
Paw-withdrawal latency was tested 30 min after morphine injection on days 1 and 7 following a daily intrathecal delivery of saline (10 μl),
morphine (M, 15 μg/10 μl) alone or in combination with KN93 (KN, 15 nmol/10 μl), a CaMKII inhibitor, PD98059 (PD, 10 μg/10 μl), an MEK (ERK
upstream kinase) inhibitor or SB203580 (SB, 10 μg/10 μl), a p38 inhibitor for 7 days. KN, PD and SB were administered 30 min before morphine
injection. Data are expressed as mean ± SEM of 7-8 animals. *p < 0.01 vs saline group on day 1. #p < 0.01 vs morphine group on day1. $p <
0.01 vs morphine group on day 7.
Figure 2 Cumulative dose-response curve of the antinociceptive effects of acute intrathecal injection of morphine in animals
previously receiving saline, KN93 (15 nmol), PD98059 (PD, 10 μg), SB203580 (SB, 10 μg), morphine (M) or morphine with KN93 (M/
KN93, 15 nmol), PD98059 (M/PD, 10μg) or SB203580 (M/SB, 10μg). Data are expressed as mean ± SEM of 6 animals.
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Page 3 of 127-day treatment with these kinase inhibitors alone did
not significantly alter nNOS levels (additional file 1, fig-
ure 1; F(3,15) = 2.893, p = 0.094). We then examined if
the inhibition of nNOS activity affected CGRP expres-
sion in the SCDH and DRG. As shown in Figure 9, a
co-treatment with the nNOS inhibitors NG (75 μg) or
7NI (25 μg) prevented chronic morphine-induced
increase in CGRP levels both in the SCDH (two way
ANOVA, F(5,23) = 7.304, p = 0.001) and DRG (two way
ANOVA, F(5,23) = 5.071, p = 0.006) while NG (75 μg) or
7NI (25 μg) alone did not change CGRP levels in both
of these two regions (Figure 9). nNOS is mostly
enriched in neurons of the spinal dorsal horn, but not
in microglia or astrocytes (Figure 10A). CaMKII was
also predominantly seen in neurons (additional file 1,
figure 2). Furthermore, CaMKII was found to be loca-
lized in nNOS-expressing cells (Figure 10B), suggesting
their co-localization. Finally, we also examined possible
changes in nNOS levels in the DRG and no differences
were observed (data not shown).
Discussion
In the present study, we investigated intracellular signal-
ing molecule(s) involved in the regulation of CGRP
known to participate in the development of tolerance to
morphine’s analgesia. Our data suggest a role of ERK,
Figure 3 Effects of the co-administration of various indicated inhibitors on chronic morphine-induced CGRP up-regulation in the
spinal cord dorsal horn. A) Western blot analysis revealed an increase in CGRP level following a daily intrathecal delivery of morphine (M, 15
μg/day) for 7 days, an effect prevented by a co-treatment with a MEK inhibitor, PD98059 (PD, 10 μg); a p38 inhibitor, SB203580 (SB, 10 μg); or a
CaMKII inhibitor, KN93 (KN, 15 nmol). Data are expressed as mean ± SEM of 4 animals. *p < 0.01 vs saline (NS) group. #p < 0.05 vs morphine
group. ##p < 0.01 vs morphine group. B and C) The immunohistochemical analysis showed that a 7-day treatment with morphine (15 μg/day)
increased CGRP levels (Bc, d and Cc, d) when compared with the saline group (Ba, b and Ca, b), an effect inhibited by the co-administrationof
PD (10 μg, Be, f), SB (10 μg, Bg, h) or KN (15 nmol, Ce, f). Scale bar, 200 μm (Ba-h, Ca-f).
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phosphorylation of these kinases in the SCDH while
their inhibitions prevented chronic morphine-induced
CGRP increases as well as the development of tolerance
to morphine-induced analgesia. The CGRP-related
regulatory processes may involve retrograde signaling
via the NO signal transduction system because the level
of nNOS, a major NO-synthesizing enzyme, is increased
in the SCDH following chronic morphine treatment and
can be modulated by the inhibition of either ERK or
p38 or CaMKII pathway. Moreover, the blockade of
nNOS also inhibited chronic morphine-induced
increases in CGRP level. The morphological data
showed that CaMKII and nNOS are co-localized in neu-
rons of the SCDH. In the DRG, increased CaMKII acti-
vation/phosphorylation was observed in CGRP-
expressing neurons in morphine-tolerant animals. Taken
together, chronic morphine-induced CGRP up-regula-
tion in both the DRG and SCDH likely involves the acti-
vation of spinal ERK, p38 and CaMKII as signaling
molecules, a process also requiring nNOS. Additionally,
the activation of CaMKII in the DRG may directly influ-
ence the expression of CGRP required for the develop-
ment of tolerance to morphine-induced analgesia.
The neuropeptide CGRP has been proposed to play an
important role in spinal nociceptive processing [20,21].
Once released, CGRP can act both pre- and post-synap-
tically on functional CLR/RAMP1 family 3 GPCR recep-
tors [22], leading to the activation of various
downstream signaling molecules including protein
kinase A (PKA), PKC, CaMKII and MAP kinase
involved in the multiple and complex pathophysiological
effects induced by CGRP [22-24]. We have previously
demonstrated a major role of CGRP and its receptors in
the pathogenesis of morphine antinociceptive tolerance
[3-6]. Specifically, blockade of CGRP receptors using
peptide (CGRP8-37) as well as non-peptide
(BIBN4096BS) CGRP receptor antagonists prevented the
Figure 4 Western blot analyses of the phosphorylation of ERK, p38 and CaMKII in the spinal cord dorsal horn following a chronic
morphine treatment. A 7-day treatment with morphine (M, 15 μg) increased the phosphorylated levels of ERK, p38 and CaMKII on day 7. Data
are expressed as mean ± SEM of 4 animals. *p < 0.01 vs saline (NS) group.
Figure 5 Inhibition of chronic morphine-induced CGRP up-
regulation by the co-administration of various inhibitors.
Western blot analyses revealed that a 7-day treatment with
morphine (M, 15 μg) increases CGRP levels in the DRG. This effect
was blocked by the co-delivery of PD98059 (MEK inhibitor, PD, 10
μg), SB203580 (p38 inhibitor, SB, 10 μg) or KN93 (CaMKII inhibitor,
KN, 15 nmol). Data are expressed as mean ± SEM of 4 animals. *p <
0.01 vs saline (NS) group. #p < 0.01 vs morphine group.
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Page 5 of 12development of tolerance to morphine-induced analgesia
as well as chronic morphine-induced CGRP up-regula-
tion in the DRG and SCDH [3-6]. Several kinases
including ERK, p38 and CaMKII have also been sug-
gested to be involved in the development of tolerance to
morphine-induced analgesia [5,6,25,26] and their activa-
tion can be regulated by the blockade of CGRP receptor
signaling [5,6]. Therefore it was deemed to be of major
interest to investigate the link between CGRP expres-
sion/regulation and kinase activities in the development
of tolerance to morphine-induced analgesia. Accord-
ingly, we examined the activity of the aforementioned
kinases in both DRG and SCDH in tolerant animals. In
agreement with earlier studies [5,6,25,26], ERK, p38 and
CaMKII showed increased levels in their phosphoryla-
t i o n / a c t i v a t i o ni nt h eS C D H .W et h e nu s e ds p e c i f i c
inhibitors to block each of the three kinase pathways.
These various inhibitors blocked chronic morphine-
induced CGRP increases in both DRG and SCDH.
These data strongly suggest an existence of a key rela-
tionship between CGRP expression/regulation and these
kinases in the development of tolerance to morphine-
induced analgesia.
It is well established that CGRP is predominantly
derived from nerve terminals of the DRG primary affer-
ent fibers in the SCDH [10]. Available data have also
shown that activated/phosphorylated ERK and p38
kinases are expressed in glial cells in the SCDH [5-7,26]
while activated CaMKII is mostly present in neurons
[ 6 ] .H e n c e ,h o wi si tt h a tm e s s e n g e r se x p r e s s e di nb o t h
neurons and glia can have similar effects on the modula-
tion of CGRP observed in morphine tolerant animals? It
is known that as a diffusible molecule, NO plays a cru-
cial role in the development of morphine analgesic
Figure 6 Western blot analyses of the phosphorylation of ERK, p38 and CaMKII in the DRG following a chronic morphine treatment.A
7-day treatment with morphine (M, 15 μg) increased the level of phosphorylated CaMKII, but not those of ERK or p38. Data are expressed as
mean ± SEM of 4 animals. *p < 0.05 vs saline (NS) group. **p < 0.01 vs saline group.
Figure 7 Double immunofluorescence staining shows that phosphorylated CaMKII (p-CaMKII, green) is expressed in CGRP-expressing
(red) DRG neurons. Arrows show their co-localization (yellow; asterisk). Scale bar, 20 μm.
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Page 6 of 12Figure 8 Chronic morphine-induced increases in nNOS are inhibited by the co-administration of various inhibitors.W e s t e r nb l o t
analyses revealed that a 7-day treatment with morphine (M, 15 μg) increased nNOS levels in the spinal cord dorsal horn, an effect inhibited by
the co-delivery of PD98059 (MEK inhibitor, PD, 10 μg), SB203580 (p38 inhibitor, SB, 10 μg) or KN93 (CaMKII inhibitor, KN, 15 nmol). Data are
expressed as mean ± SEM of 4 animals. *p < 0.01 vs saline (NS) group. #p < 0.01 vs morphine group.
Figure 9 Western blot analyses of CGRP levels in the DRG and spinal cord dorsal horn (SCDH) following chronic treatments with
saline (NS), NG (a nNOS inhibitor, 75 μg), 7-NI (an nNOS inhibitor, 25 μg) and morphine (M, 10 μg) alone or in combination with NG
(75 μg) or 7-NI (25 μg). A 7-day treatment with morphine increased CGRP levels in both the DRG and SCDH, effects inhibited by the co-
administration of the nNOS inhibitors NG and 7-NI. *p < 0.01 vs respective saline group. #p < 0.01 vs respective morphine group.
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Page 7 of 12tolerance [27,28]. Once released, NO can exert its
effects either via the activation of the soluble guanylate
cyclase (sGC)-cyclic GMP (cGMP) pathway [29,30] or
directly by modulating gene expression through its S-
nitrosylation of target proteins [31]. Therefore, we
hypothesize that NO can act as an intermediate linking
the activation of kinases to CGRP expression during the
development of tolerance to morphine-induced analge-
sia. In support of this hypothesis, our data have demon-
strated significant increases in nNOS levels in the
Figure 10 Immunohistochemical staining and distribution of nNOS-ir cells in the spinal cord dorsal horn (Aa).D o u b l e
immunofluorescence staining revealed that nNOS is mostly enriched in NeuN-ir (arrows, Ad-f,) but not in GFAP- (green, Ab) or OX-42-ir (green,
Ac) cells. B) nNOS-expressing cells also express CaMKII (arrows, Ba-c). Scale bars, 25 μm (Aa); 20 μm (Ab-f, Ba-c).
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can be prevented by the inhibition of the ERK, p38 and
CaMKII pathways. In addition, both CaMKII and nNOS
are co-localized, suggesting the existence of a CaMKII-
nNOS cascade regulating CGRP expression following
chronic morphine treatment. As mentioned earlier, both
ERK and p38 are mostly expressed in glial cells, suggest-
ing an indirect effect by the modulation of these kinases.
Interestingly, the inhibition of nNOS activity largely
blocks chronic morphine-induced CGRP up-regulation
in the DRG and SCDH, indicating that NO may act as a
retrograde signaling molecule to regulate presynaptic
CGRP expression levels. Taken together, these data sug-
gest that chronic morphine-induced CGRP up-regula-
tion involves the activation of a neuronal CaMKII-
nNOS pathway, a process that can be regulated by the
activation of ERK and p38 via a glial-neuronal cell
interaction.
I ts h o u l db en o t e dt h a tt h ew e s t e r nb l o ta n a l y s e sd i d
not reveal any increases in the phosphorylation of ERK
and p38 in DRG extracts. In contrast, a chronic mor-
phine treatment increased ERK phosphorylation in cul-
tured DRG [18] as well as the phosphorylation of ERK
and p38 in vivo [32]. However, CaMKII showed a signif-
icant increase in its phosphorylation in the DRG,
suggesting different molecular responsiveness of these
kinases to morphine exposure and the development of
tolerance. The different molecular responses could be
attributable to the differential cell localization of kinases
in the two regions, i.e. glia-localized in spinal cord and
neuron-localized in DRG. In addition, activated CaMKII
was found to be expressed in CGRP-enriched DRG neu-
rons with the inhibition of CaMKII activity decreasing
CGRP expression, suggesting that the chronic mor-
phine-induced CGRP up-regulation may also involve the
direct activation of CaMKII in DRG neurons.
In summary, a chronic morphine treatment induced
the activation of the neuronal CaMKII-nNOS pathway
in the SCDH, thereby resulting in increased NO release.
The released NO diffuses to presynaptic nerve terminals
to retrogradely modulate CGRP gene expression via the
direct activation of the sGC-cGMP pathway [29,30] or
the S-nitrosylation [31] of related nuclear proteins (Fig-
ure 11A). The effects of glial ERK and p38 [5,6,26] on
the expression of CGRP in the SCDH likely occur
through the regulation of neuronal CaMKII-nNOS sig-
naling (Figure 11B). In the DRG, a chronic morphine
treatment can enhance CaMKII activation resulting in
CGRP gene expression via the modulation of transcrip-
tional activities leading to tolerance to opiate-induced
Figure 11 Schematic models of the mechanisms underlying the regulation of CGRP during the development of tolerance to
morphine-induced analgesia. A chronic morphine treatment induces the activation of the neuronal CaMKII-nNOS pathway in the SCDH,
resulting in an increased NO release. NO can then retrogradly diffuse to the presynaptic nerve terminals to modulate CGRP gene expression
either via direct activation of the sGC-cGMP pathway [29,30] or via the S-nitrosylation [31] of related nuclear proteins. The effects of glial ERK and
p38 on CGRP expression in the SCDH may occur through the regulation of neuronal CaMKII-nNOS signaling. B) In the DRG, chronic morphine
enhances the activation of CaMKII, which can then stimulate CGRP gene expression via the modulation of various transcriptional factors.
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development of tolerance and blockers of the pathways
and/or molecules involved could prove most useful in
various pathophysiological conditions.
Methods
All animal experiments were approved by the Animal
Care and Use Committee of McGill University as well
as Canadian Council on Animal Care and performed
according to the guidelines of the International Associa-
tion for the Study of Pain concerning the use of labora-
tory animals.
Operative procedures and drug delivery
Intrathecal catheterization was performed on male Spra-
gue-Dawley rats weighing 230-250 g as previously
described [5-7]. Specifically, under isoflurane anesthesia,
a polyethylene (PE)-10 tubing was implanted into the
subarachnoid space through the gap between the verteb-
rae L5 and L6 and extended to the caudal part of the
lumbar enlargement. The remaining portion of the tub-
ing was partly sutured to the neighboring musculature
and exited through a small hole at the back of the neck.
Animals were allowed to recover for 7-9 days before
behavioral experiments and were acclimated to the test-
ing environment. Drugs were injected through the exter-
ior end of the tubing in a total volume of 10 μl followed
by a flush of 15 μl of saline. Drug doses were chosen in
accordance with previous studies [3,5,6,26,33]. The fol-
lowing drugs were purchased from Sigma-Aldrich (St.
Louis, MO, USA): morphine sulfate (1.5 μg/μl in saline),
4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyri-
dyl)1H-imidazole (SB203580; 1 μg/μl in 20% DMSO)
and 2’-amino-3’-methoxyflavone (PD98059; 1 μg/μli n
20% DMSO) while 2-[N-(2-hydroxyethyl)]-N-(4-methox-
ybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-
methylbenzylamine)phosphate (KN93; 1.5 mM in 20%
DMSO), 7-Nitroindazole (7-NI; 2.5 μg/μl in 20%
DMSO) and (4S)-N-(4-amino-5[aminoethyl]aminopen-
tyl)-N’-nitroguanidine, TFA (NG; 7.5 μg/μl in 20%
DMSO) were purchased from Calbiochem (San Diego,
CA, USA).
Behavioral testing
The standard regimen of daily intrathecal injection of
morphine (15 μg/day for 7 days) was used to induce
analgesic tolerance to morphine as previously described
[3,5,34]. Analgesic effectso fm o r p h i n ew e r ee v a l u a t e d
by paw-withdrawal latency. Specifically, a radiant heat
beam was focused on the plantar surface of the hindpaw
[35]. The thermal stimulation intensity was adjusted to
produce a baseline latency of 10-12 sec and a cut-off
time of 25 sec was used to prevent any potential tissue
injury. Paw-withdrawal response latency was defined as
the time from the onset of radiant heat to paw withdra-
wal and measured automatically by a digital meter. We
conducted behavioral testing before and 30 min after
drug injection on days 1 and 7. Data were standardized
by conversion to percentage of maximal possible effect
(%MPE) according to the following formula: [(response
latency-baseline latency)/(cut-off time-baseline
latency)]×100.
On day 8 ascending doses of morphine were acutely
injected to animals previously receiving various chronic
treatments through the intrathecal catheter every 30
min until a maximal analgesic effect was achieved in the
tail-flick test, as previously reported [3,6]. The cumula-
tive dose-response curve of the antinociceptive effect of
acute morphine was constructed accordingly. A non-lin-
ear regression analysis was used to determine the ED50
values while their statistical significance was computed
using one-way ANOVA followed by a student-Newman-
Keuls (SNK) post-hoc test for comparisons between
groups. The standardized behavioral data were
expressed as mean ± SEM and analyzed by two-way
repeated ANOVA with a SNK post hoc test.
Immunohistochemistry
Animals were perfused via the ascending aorta with
300 ml of 4% paraformaldehyde following a flush of
100-150 ml saline. The lumbar spinal cords (L4 and 5)
and corresponding DRGs were harvested, post-fixed in
the same fixative for 4 h at 4°C and then transferred to
30% sucrose overnight for cryoprotection. DRG (16
μm) and transverse spinal cord sections (35 μm) were
cut on a cryostat and collected for immunohistochem-
ical studies.
Single labeling of CGRP
To remove endogenous peroxidase activity, floating
spinal cord sections were treated with 0.03% H2O2 for
15 min. Next, to block any non-specific binding and
enhance membrane permeability, sections were pro-
cessed with 10% normal donkey serum and 0.03%
TrionX-100 in 0.01 M PBS at room temperature (RT)
for 30 min. Sections were incubated at 4°C with the pri-
mary guinea pig anti-CGRP antibody (1:3000, Peninsula
Labs, San Carlos, CA, USA) for 48 hr. After rinsing in
0.01 M PBS, sections were incubated at RT in biotiny-
lated donkey anti-guinea pig IgG for 1 h followed by
reaction with avidin-biotin-peroxidase complex (ABC)
for 30 min using Vectastain ABC kit (Vector, Burlin-
game, CA, USA). The immunoprecipitates were devel-
oped in 0.05% diaminobenzidine with 0.01% hydrogen
peroxide and intensified by the addition of 0.02% nickel
ammonium sulfate. In addition, CGRP fluorescent stain-
ing (1:500) was performed with the same primary anti-
body and visualized using Alexa488-conjugated donkey
anti-guinea pig secondary antibody.
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To reveal if CaM kinase II (CaMKII) can be activated in
CGRP-expressing neurons, DRG sections were incu-
bated with a mixture of rabbit anti-p-CaMKII (1:400)
and guinea pig anti-CGRP (1:500). To identify the cell
type(s) expressing nNOS or CaMKII, spinal sections
were incubated with a mixture of rabbit anti-nNOS (or
rabbit anti-CaMKII) and mouse anti-glial fibrillary acidic
protein (GFAP, an astroglial marker, 1:1000, Millipore,
Billerica, MA, USA), or mouse anti-OX-42 (a microglial
marker, 1:100, AbD Serotech, Raleigh, NC, USA) or
mouse anti-NeuN (a neuronal marker, 1:1000, Millipore)
antibodies. Spinal sections were also incubated with a
mixture of goat anti-nNOS and rabbit anti-CaMKII to
determine if these two molecules are co-localized.
Western blotting
Animals were rapidly perfused through the ascending
aorta with 100-150 ml of saline under anesthesia and
the L4-L6 spinal cords and corresponding DRGs were
collected on dry ice and stored at -80°C. Tissues were
homogenized in modified RIPA buffer (50 mM Tris-
HCl, 150 mM NaCl, 1 mM EDTA, 1% Igepal CA-630,
0.1% SDS, 50 mM NaF, and 1 mM NaVO3) containing a
mixture of protein inhibitors (Sigma) including PMSF (2
mM), leupeptin (10 μg/ml) as well as aprotinin (10 μg/
ml) and protein concentrations were determined by
using a BCA protein assay kit (Pierce Biotechnology,
Rockford, IL, USA). Equal amounts of protein samples
(20 μg / l a n e )w e r el o a d e da n ds e p a r a t e do nS D S - P A G E
gels (4-20% tris-glycine gels, Invitrogen, Carlsbad, CA,
USA; for CGRP, 18% tris-glycine gels were also
included) and electroblotted onto Hybond-C nitrocellu-
lose membranes (Amersham Biosciences, Piscataway,
NJ, USA). The membranes were then processed for 1 h
at RT with 5% skim milk to block non-specific binding
sites and incubated overnight at 4°C with various indi-
cated primary antibodies. After rinsing in 1xTBST,
membranes were further incubated with HRP-conju-
gated secondary antibodies for 1 h at RT, developed in
ECL solution for 1-5 min and exposed onto X-films for
1-5 min. Antibodies including p-ERK, p-p38 and p-
CaMKII were purchased from Cell Signaling Technology
and used at a dilution of 1:1000 while CGRP (1:1000)
was obtained from Peninsula Labs and nNOS (1:800)
from Santa Cruz Biotechnology. For loading controls,
membranes were incubated with a stripping buffer and
reprobed with antibodies against ERK, p38 and CaMKII
at a dilution of 1:1000 (Cell Signaling Technology) as
well as beta-actin at a dilution of 1:5000 (Santa Cruz
Biotechnology). Specific bands were captured using a
Sierra Scientific MS-4030 video camera (Sierra Scientific,
Sunnyvale, CA, USA)and quantified by densitometric
analysis using MCID version 6 Elite imaging software
(Imaging Research, St. Catharines, ON, Canada). The
density of each target band was normalized with its cor-
responding internal loading control bands. The fold
change was defined as the ratio of the normalized data
of the treatment group relative to its control group.
Data are expressed as mean ± SEM. Statistical signifi-
cance was analyzed using one-way or two-way ANOVA,
wherever appropriate followed by a SNK post hoc test
for comparisons between groups.
Additional material
Additional file 1: Additional figures 1 and 2. The file contains two
figures, additional Figures 1 and 2.
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